An interventional study of Noxsano Bandage (Healthy Volunteers) and Noxsano Bandage (Wound Care) in Wound Heal, Peripheral Artery Disease and Ulcer, Leg, sponsored by OhioHealth. Terminated at 1 site in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by OhioHealth · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 309th largest by enrollment of the 373 interventional ones that give a count, is one of 24 that started in 2019, is one of 217 with no phase, and was the 317th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Japan, United Kingdom
Ages 18+
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–55 · Healthy volunteers
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 18+
Cook Research Incorporated · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
479 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 65 · Phase 3 35 · Phase 4 25
First in 1992; this study’s year is marked. 24 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 64 across the 373 interventional studies, 125 across the 103 observational. Of the 335 that completed or were terminated, 155 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
189 of 479 have an industry lead sponsor. The 10 most frequent:
OhioHealth is the lead sponsor of 25 studies on the registry; none are open to participants now.
OhioHealth has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
36 of the studies in Peripheral Arterial Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04794530Phase 3Northwestern UniversityThe COCOA-PAD II Trial | 2026-12-31 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06321575Nipro Vascular Innovations Americas, IncThe Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial) | 2026-11 |
| NCT05916950Philips Clinical & Medical Affairs GlobalThe THOR IDE Study | 2026-12 |
Add all 36 to your calendar (.ics) → With an account.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, interventional, non-randomized study designed to assess the safety and efficacy of the Noxsano Bandage (study device) in healthy subjects and wound care subjects with a diabetic lower extremity ulceration and/or arterial insufficiency lower extremity ulceration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group 1: Subjects must meet all of the following criteria to be eligible for enrollment:
Group 2: Subjects must meet all of the following criteria to be eligible for enrollment:
Subject with at least one of the following:
Exclusion Criteria:
Group 1: Subjects will be excluded from the trial if any of the following criteria are met:
Group 2: Subjects will be excluded from the trial if any of the following criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The initial phase of the study is designed to determine the safety of the study device, the Noxsano Bandage, in healthy volunteers without wounds.
Device: Noxsano Bandage (Healthy Volunteers)
The second phase of the study is designed to determine the effectiveness of the study device in wound healing in subjects with active wounds.
Device: Noxsano Bandage (Wound Care)
Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
Adverse Events - Healthy Volunteers
Adverse events related to the Noxsano bandage will be assessed using a safety and adverse reactions questionnaire that includes questions for the subject regarding tolerance, side effects, and adverse events.
Time frame: 4 weeks post-bandage removal
Wound Surface Area
Wound surface area will be measured using a horizontal and vertical measurement taken in centimeters (cm) using a standard ruler. These measurements are used to calculate wound area in centimeters squared (cm2).
Time frame: change in baseline wound area at 2 months
Adverse Events - Wound Care Subjects
Adverse events related to the Noxsano bandage will be assessed using a safety and adverse reactions questionnaire that includes questions for the subject regarding tolerance, side effects, and adverse events.
Time frame: 12 months post-treatment
| Milestone | Healthy Volunteers | Wound Care |
|---|---|---|
| Started | 11 | 0 |
| Baseline visit | 10 | 0 |
| Completed | 10 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Subject did not show up for baseline visit and was replaced | 1 | 0 |
| Milestone | Healthy Volunteers | Wound Care |
|---|---|---|
| Started | 0 | 2 |
| Baseline visit | 0 | 2 |
| Completed | 0 | 0 |
| Not completed | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Adverse events related to the Noxsano bandage will be assessed using a safety and adverse reactions questionnaire that includes questions for the subject regarding tolerance, side effects, and adverse events.
| Participants | Healthy Volunteers |
|---|---|
| Adverse Events - Healthy Volunteers | 3 |
Wound surface area will be measured using a horizontal and vertical measurement taken in centimeters (cm) using a standard ruler. These measurements are used to calculate wound area in centimeters squared (cm2).
No measurements were reported for this outcome.
Adverse events related to the Noxsano bandage will be assessed using a safety and adverse reactions questionnaire that includes questions for the subject regarding tolerance, side effects, and adverse events.
No measurements were reported for this outcome.
Collected over Adverse event data was collected up to 4 weeks for Healthy Volunteers and up to 13 months for Wound Care participants.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Volunteers | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Wound Care | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Event | Healthy Volunteers | Wound Care |
|---|---|---|
| PainSkin and subcutaneous tissue disorders | 0/10 | 1/2 |
| Event | Healthy Volunteers | Wound Care |
|---|---|---|
| itchy skinSkin and subcutaneous tissue disorders | 7/10 | 1/2 |
| dry dkinSkin and subcutaneous tissue disorders | 5/10 | 1/2 |
| painSkin and subcutaneous tissue disorders | 2/10 | 1/2 |
| red skinSkin and subcutaneous tissue disorders | 1/10 | 1/2 |
| swollen skinSkin and subcutaneous tissue disorders | 2/10 | 1/2 |
| skin discolorationSkin and subcutaneous tissue disorders | 5/10 | 0/2 |
| skin darkeningSkin and subcutaneous tissue disorders | 0/10 | 1/2 |
| pressure soresSkin and subcutaneous tissue disorders | 0/10 | 1/2 |
| bruiseSkin and subcutaneous tissue disorders | 2/10 | 0/2 |
| skin flakingSkin and subcutaneous tissue disorders | 1/10 | 0/2 |
| Age, Categorical(Participants) | Healthy Volunteers | Wound Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 0 | 9 |
| >=65 years | 1 | 2 | 3 |
| Age, Continuous(years) | Healthy Volunteers | Wound Care | Total |
|---|---|---|---|
| Mean | 39.9 ± 13.4 | 69.5 ± 0.5 | 44.8 ± 16.5 |
| Sex: Female, Male(Participants) | Healthy Volunteers | Wound Care | Total |
|---|---|---|---|
| Female | 6 | 1 | 7 |
| Male | 4 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Healthy Volunteers | Wound Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 1 | 6 |
| White | 5 | 1 | 6 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Healthy Volunteers | Wound Care | Total |
|---|---|---|---|
| United States | 10 | 2 | 12 |
| Body Mass Index(kilograms pre meter squared) | Healthy Volunteers | Wound Care | Total |
|---|---|---|---|
| Mean | — | 29.8 ± 1.0 | 29.8 ± 1.0 |
| Height(centimeters) | Healthy Volunteers | Wound Care | Total |
|---|---|---|---|
| Mean | — | 175.3 ± 5.1 | 175.3 ± 5.1 |
| Hemoglobin A1c(mmol/mol) | Healthy Volunteers | Wound Care | Total |
|---|---|---|---|
| Mean | — | 7.8 ± 0.7 | 7.8 ± 0.7 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Sep 2020, 13 months.
Results were first posted in Dec 2023, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OhioHealth